JP2020517611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517611A5 JP2020517611A5 JP2019556610A JP2019556610A JP2020517611A5 JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5 JP 2019556610 A JP2019556610 A JP 2019556610A JP 2019556610 A JP2019556610 A JP 2019556610A JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5
- Authority
- JP
- Japan
- Prior art keywords
- mesylate salt
- salt according
- organic solvent
- represented
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCNC(C*(C)CC*(C)(C)C)**C Chemical compound CCNC(C*(C)CC*(C)(C)C)**C 0.000 description 6
- HAFZSBASGRZPLA-UHFFFAOYSA-N CCC(C)N(C)CC Chemical compound CCC(C)N(C)CC HAFZSBASGRZPLA-UHFFFAOYSA-N 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129468A JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0051687 | 2017-04-21 | ||
| KR20170051687 | 2017-04-21 | ||
| PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129468A Division JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517611A JP2020517611A (ja) | 2020-06-18 |
| JP2020517611A5 true JP2020517611A5 (https=) | 2021-04-30 |
| JP7126514B2 JP7126514B2 (ja) | 2022-08-26 |
Family
ID=63857137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556610A Active JP7126514B2 (ja) | 2017-04-21 | 2018-04-18 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
| JP2022129468A Active JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129468A Active JP7390444B2 (ja) | 2017-04-21 | 2022-08-16 | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11453656B2 (https=) |
| EP (1) | EP3612529A4 (https=) |
| JP (2) | JP7126514B2 (https=) |
| KR (3) | KR102629654B1 (https=) |
| CN (1) | CN110869367B (https=) |
| AR (1) | AR111469A1 (https=) |
| AU (2) | AU2018256227B2 (https=) |
| CA (1) | CA3059543A1 (https=) |
| CO (1) | CO2019011578A2 (https=) |
| EA (1) | EA201992501A1 (https=) |
| IL (2) | IL270018B (https=) |
| MA (1) | MA49696A (https=) |
| MX (2) | MX392634B (https=) |
| MY (1) | MY201919A (https=) |
| NZ (1) | NZ758443A (https=) |
| PH (1) | PH12019502370A1 (https=) |
| SA (1) | SA519410342B1 (https=) |
| SG (1) | SG11201909615YA (https=) |
| TW (1) | TWI776882B (https=) |
| UA (1) | UA124364C2 (https=) |
| WO (1) | WO2018194356A1 (https=) |
| ZA (1) | ZA201907687B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| WO2020125391A1 (zh) * | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| WO2020230091A1 (en) * | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| AU2020275272A1 (en) * | 2019-05-14 | 2021-12-02 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| PH12022552076A1 (en) | 2020-02-12 | 2023-11-29 | Janssen Biotech Inc | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS |
| PH12022552454A1 (en) * | 2020-04-14 | 2024-02-05 | Janssen Biotech Inc | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| WO2022253261A1 (zh) | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1698623T3 (pl) | 2003-12-25 | 2015-08-31 | Eisai R&D Man Co Ltd | Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania |
| US8048883B2 (en) | 2004-02-11 | 2011-11-01 | Natco Pharma Limited | Polymorphic form of imatinib mesylate and a process for its preparation |
| TWI546290B (zh) * | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| MX2012005332A (es) | 2009-11-13 | 2012-10-15 | Oscotec Inc | Inhibidores de cinasa. |
| WO2012077136A2 (en) | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| CN103702990B (zh) * | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| CN104540822B (zh) | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| EP3929190B1 (en) * | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN104788427B (zh) | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| KR101794186B1 (ko) | 2015-10-30 | 2017-11-08 | 한국기술교육대학교 산학협력단 | 전기자동차용 급전장치 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es not_active Application Discontinuation
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 MX MX2019012574A patent/MX392634B/es unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active Active
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en not_active Ceased
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
-
2019
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486B2/en active Active
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR102835717B1/ko active Active
-
2024
- 2024-03-27 US US18/618,379 patent/US12428401B2/en active Active
-
2025
- 2025-07-11 KR KR1020250093917A patent/KR20250111074A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517611A5 (https=) | ||
| TWI640509B (zh) | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 | |
| TWI597277B (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第ｉ型結晶及製備方法 | |
| JP6158811B2 (ja) | ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリルの結晶多形およびその製造方法 | |
| CN115461344B (zh) | 一种glp-1受体激动剂的晶型a及其制备方法 | |
| JP6830888B2 (ja) | Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法 | |
| JP2020033359A5 (https=) | ||
| TWI860993B (zh) | 唑化合物晶體 | |
| WO2012155806A1 (zh) | 4-氨基喹唑啉衍生物及其应用 | |
| WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| JP2019504033A (ja) | 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法 | |
| JP7314319B2 (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JP2023553021A (ja) | ピロロピリミジン系化合物の塩、その結晶及びその使用 | |
| JP2025114691A (ja) | オキサゾール化合物結晶 | |
| CN111989329A (zh) | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 | |
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| CN104628677A (zh) | 一种沃替西汀有机酸盐晶型及其制备方法 | |
| CN101277694B (zh) | 盐酸伊立替康的新晶形 | |
| CN104610195A (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
| US11390597B2 (en) | Salt and solid state forms of escitalopram | |
| JPWO2020151756A5 (https=) | ||
| JP2018509421A (ja) | ニンテダニブジエタンスルホン酸塩結晶並びにその製造方法および使用 | |
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| CN118525012A (zh) | 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用 | |
| JP2018500355A5 (https=) |